A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
CONTEXT: As many as 1 in every 110 children in the United States has an autism spectrum disorder (ASD). Many medical treatments for ASDs have been proposed and studied, but there is currently no consensus regarding which interventions are most effective. OBJECTIVE: To systematically review evidence regarding medical treatments for children aged 12 years and younger with ASDs. METHODS: We searched the Medline, PsycInfo, and ERIC (Education Resources Information Center) databases from 2000 to May 2010, regulatory data for approved medications, and reference lists of included articles. Two reviewers independently assessed each study against predetermined inclusion/exclusion criteria. Studies of secretin were not included in this review. Two reviewers independently extracted data regarding participant and intervention characteristics, assessment techniques, and outcomes and assigned overall quality and strength-of-evidence ratings on the basis of predetermined criteria. RESULTS: Evidence supports the benefit of risperidone and aripiprazole for challenging and repetitive behaviors in children with ASDs. Evidence also supports significant adverse effects of these medications. Insufficient strength of evidence is present to evaluate the benefits or adverse effects for any other medical treatments for ASDs, including serotonin-reuptake inhibitors and stimulant medications. CONCLUSIONS: Although many children with ASDs are currently treated with medical interventions, strikingly little evidence exists to support benefit for most treatments. Risperidone and aripiprazole have shown benefit for challenging and repetitive behaviors, but associated adverse effects limit their use to patients with severe impairment or risk of injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“citalopram has demonstrated poor tolerability and no benefit for repetitive behaviour in children with ASD 208 .”
From Autism spectrum disorder (2020) · cites this paper as [208]
In the citing paper
“Although these drugs serve to manage challenging and repetitive behaviors, they have little effect on the social communication deficit observed in ASD 88 .”
From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [88]
In the citing paper
“These two agents, Risperdal and Abilify (11), do not target the core symptoms, but rather treat a cluster of associated symptoms referred to as irritability.”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [11]
In the citing paper
“Therefore, therapeutic efficacy is currently evaluated by improvement in the diagnostic behavioral symptoms (11, 50, 95).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [11]
In the citing paper
“Dysfunction in the dopamine system in ASD has been suggested, based on the beneficial effects of dopamine receptor antagonists (for example, antipsychotic drugs such as risperidone) in treating certain symptoms commonly exhibited by affected individuals, such as stereotypies, aggression, hyperactivity, and self-injury [123].”
From Social “wanting” dysfunction in autism: neurobiological underpinnings and treatment implications (2012) · cites this paper as [123]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Educating Children with Autism
Lord, C. (2001) · Cited by 1,499
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Cited by
Lai, M.-C., Lombardo, M. V., & Baron-Cohen, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61539-1 · Cited by 2,371
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Self-citationIdentification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options
Masi, A., DeMayo, M. M., Glozier, N., & Guastella, A. J. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0100-y · Cited by 987
“While there are promising indications for new medical treatments for autism [100], a recent systematic review found that while many children with ASDs are treated with medical interventions, there is minimal evidence to support the benefit of most treatments [101].”
BackgroundBig data approaches to decomposing heterogeneity across the autism spectrum
Lombardo, M. V., Lai, M.-C., & Baron-Cohen, S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0321-0 · Cited by 537
“significantly affect the core characteristics of autism [65, 66].”
BackgroundBehavioural and emotional disorders in childhood: A brief overview for paediatricians
Ogundele, M. O. (2018) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v7.i1.9 · Cited by 471
GABA system dysfunction in autism and related disorders: From synapse to symptoms
Coghlan, S., Horder, J., Inkster, B., Mendez, M. A., Murphy, D. G., & Nutt, D. J. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.07.005 · Cited by 446
Evidence Base Update for Autism Spectrum Disorder
Smith, T., & Iadarola, S. (2015) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2015.1077448 · Cited by 339
Autism: A “Critical Period” Disorder?
LeBlanc, J. J., & Fagiolini, M. (2011) · Neural Plasticity · doi:10.1155/2011/921680 · Cited by 301
“Finally, in the case of autism, no single treatment has been shown to have consistent positive results, thereby also making predictive validity complicated [18].”
Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review
Jobski, K., Höfer, J., Hoffmann, F., & Bachmann, C. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12644 · Cited by 263
Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486
Dolan, B. M., Duron, S. G., Campbell, D. A., Vollrath, B., Rao, B. S. S., Ko, H.-Y., Lin, G. G., Govindarajan, A., Choi, S.-Y., & Tonegawa, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219383110 · Cited by 260
Qin, L., Ma, K., Wang, Z.-J., Hu, Z., Matas, E., Wei, J., & Yan, Z. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0110-8 · Cited by 240
Silverman, J. L., Smith, D. G., Rizzo, S. J. S., Karras, M. N., Turner, S. M., Tolu, S. S., Bryce, D. K., Smith, D. L., Fonseca, K., Ring, R. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003501 · Cited by 251
Taliou, A., Zintzaras, E., Lykouras, L., & Francis, K. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.04.006 · Cited by 233
Guastella, A. J., & Hickie, I. B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.028 · Cited by 223
“Risperidone and ariprazole have shown benefit in reducing hyperactivity and aggressive, self-injurious, and repetitive behaviour (22, 28), but are associated with significant negative side effects.”
Progress toward treatments for synaptic defects in autism
Delorme, R., Ey, E., Toro, R., Leboyer, M., Gillberg, C., & Bourgeron, T. (2013) · Nature Medicine · doi:10.1038/nm.3193 · Cited by 218
A Short Review on the Current Understanding of Autism Spectrum Disorders
Park, H. R., Lee, J. M., Moon, H. E., Lee, D. S., Kim, B.-N., Kim, J., Kim, D. G., & Paek, S. H. (2016) · Experimental Neurobiology · doi:10.5607/en.2016.25.1.1 · Cited by 210
“Antipsychotics were effective in treating the repetitive behaviors in children with ASD; however, there was not sufficient evidence on the efficacy and safety in adolescents and adults [114].”
BackgroundAutism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses
Won, H., Mah, W., & Kim, E. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00019 · Cited by 206
McCoy, S. M., Jakicic, J. M., & Gibbs, B. B. (2016) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-016-2762-0 · Cited by 205
Social “wanting” dysfunction in autism: neurobiological underpinnings and treatment implications
Kohls, G., Chevallier, C., Troiani, V., & Schultz, R. T. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-10 · Cited by 197
“Dysfunction in the dopamine system in ASD has been suggested, based on the beneficial effects of dopamine receptor antagonists (for example, antipsychotic drugs such as risperidone) in treating certain symptoms commonly exhibited by affected individuals, such as stereotypies, aggression, hyperactivity, and self-injury…”
BackgroundMehta, M. V., Gandal, M. J., & Siegel, S. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026077 · Cited by 185
“Treatment with risperidone is generally limited to patients who display certain associated maladaptive behaviors, such as irritability, aggression, and self-injury [10,11], as the drug has a significant side-effect profile, including weight gain and metabolic syndrome, which complicate its therapeutic potential [12].”
BackgroundFocal brain inflammation and autism
Theoharides, T. C., Asadi, S., & Patel, A. B. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-46 · Cited by 178
“However, two recent reviews concluded that there is insufficient evidence to support any benefit of psychotropic drugs [96] or selective serotonin re-uptake inhibitor (SSRIs) [97] in ASD.”
BackgroundLv, Y.-T., Zhang, Y., Liu, M., Qiuwaxi, J.-N.-T., Ashwood, P., Cho, S. C., Huan, Y., Ge, R.-C., Chen, X.-W., Wang, Z.-J., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-196 · Cited by 174
“However, there is no defined standard treatment intervention for children with autism [7,8].”
BackgroundSubtyping cognitive profiles in Autism Spectrum Disorder using a Functional Random Forest algorithm
Feczko, E., Balba, N. M., Miranda-Dominguez, O., Cordova, M., Karalunas, S. L., Irwin, L., Demeter, D. V., Hill, A. P., Langhorst, B. H., Grieser Painter, J., et al. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2017.12.044 · Cited by 173
A Systematic Review of the Valproic-Acid-Induced Rodent Model of Autism
Chaliha, D., Albrecht, M., Vaccarezza, M., Takechi, R., Lam, V., Al-Salami, H., & Mamo, J. (2020) · Developmental Neuroscience · doi:10.1159/000509109 · Cited by 173
Veenstra-VanderWeele, J., Cook, E. H., King, B. H., Zarevics, P., Cherubini, M., Walton-Bowen, K., Bear, M. F., Wang, P. P., & Carpenter, R. L. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.237 · Cited by 168
“Many youth with ASD are also treated with medications to treat common comorbid symptoms, including irritability/agitation or hyperactivity (Fung et al, 2016; Reichow et al, 2013), but no medication has solid evidence for treating core ASD symptoms (McPheeters et al, 2011).”
BackgroundSelf-citationSharing Heterogeneous Data: The National Database for Autism Research
Hall, D., Huerta, M. F., McAuliffe, M. J., & Farber, G. K. (2012) · Neuroinformatics · doi:10.1007/s12021-012-9151-4 · Cited by 152
A quarter century of progress on the early detection and treatment of autism spectrum disorder
Dawson, G., & Bernier, R. (2013) · Development and Psychopathology · doi:10.1017/s0954579413000710 · Cited by 149
“Only two drugs have been approved by the FDA for the treatment of ASD, and those treat associated symptoms of irritability rather than core autism symptoms (McPheeters et al., 2011).”
BackgroundThe comorbidity of ADHD and autism spectrum disorder
Antshel, K. M., Zhang-James, Y., & Faraone, S. V. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.840417 · Cited by 147
Siegel, M. S., & Beaulieu, A. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1399-2 · Cited by 170
“A recent review of medical interventions for children with autism included 18 studies, 10 of which were randomized controlled trials, and found sufficient evidence for the use of risperidone and aripiprazole for irritability and challenging behavior (Mcpheeters et al. 2011).”
BackgroundAsadabadi, M., Mohammadi, M.-R., Ghanizadeh, A. J., Modabbernia, A., Ashrafi, M., Hassanzadeh, E., Forghani, S., & Akhondzadeh, S. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2796-8 · Cited by 153
Ghanizadeh, A., Sahraeizadeh, A., & Berk, M. (2014) · Child Psychiatry & Human Development · doi:10.1007/s10578-013-0390-x · Cited by 134
Reichow, B., Volkmar, F. R., & Bloch, M. H. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1793-z · Cited by 134
Ghaleiha, A., Asadabadi, M., Mohammadi, M.-R., Shahei, M., Tabrizi, M., Hajiaghaee, R., Hassanzadeh, E., & Akhondzadeh, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000880 · Cited by 132
Children on the Autism Spectrum and the Use of Virtual Reality for Supporting Social Skills
Frolli, A., Savarese, G., Di Carmine, F., Bosco, A., Saviano, E., Rega, A., Carotenuto, M., & Ricci, M. C. (2022) · Children · doi:10.3390/children9020181 · Cited by 130
RetractedVeenstra-VanderWeele, J., & Blakely, R. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.185 · Cited by 128
“Unfortunately, available treatments for ASDs are inadequate (McPheeters et al, 2011; Warren et al, 2011).”
BackgroundSelf-citationMendez, M. A., Horder, J., Myers, J., Coghlan, S., Stokes, P., Erritzoe, D., Howes, O., Lingford-Hughes, A., Murphy, D., & Nutt, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.008 · Cited by 126
“However, the efficacy of such pharmacotherapy has recently been questioned (McPheeters et al., 2011).”
STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
Erickson, C. A., Veenstra-Vanderweele, J. M., Melmed, R. D., McCracken, J. T., Ginsberg, L. D., Sikich, L., Scahill, L., Cherubini, M., Zarevics, P., Walton-Bowen, K., et al. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1963-z · Cited by 125
“Irritability, marked by severe tantrums, aggression and selfinjury, is common and impairing, but not a core deficit of the disorder.(McPheeters et al. 2011; Huffman et al. 2011) The use of these atypical antipsychotics targeting irritability associated with autistic disorder was based on empirical extension of their e…”
BackgroundSelf-citationSerotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders
Israelyan, N., & Margolis, K. G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.020 · Cited by 122
A Case Series of a Luteolin Formulation (Neuroprotek®) in Children with Autism Spectrum Disorders
Theoharides, T. C., Asadi, S., & Panagiotidou, S. (2012) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201202500201 · Cited by 120
“In fact, recent studies have shown that use of selective serotonin reuptake inhibitor (SSRI) antidepressants (5) and some antipsychotics (6) may actually worsen ASD symptoms and cause the onset of adverse effects (7).”
BackgroundZhao, H., Swanson, A. R., Weitlauf, A. S., Warren, Z. E., & Sarkar, N. (2018) · IEEE Transactions on Human-Machine Systems · doi:10.1109/thms.2018.2791562 · Cited by 137
“cific scenarios [5], [11]–[16].”
Self-citationFallah, M. S., Shaikh, M. R., Neupane, B., Rusiecki, D., Bennett, T. A., & Beyene, J. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0115 · Cited by 115
“Behavioral interventions to treat antecedents, alter environments, and support parents in management of impulsivity and aggression are preferred, but in highly aggressive or persistently irritable youth, medications are often important interventions (McPheeters et al. 2011).”
Medications for Adolescents and Young Adults With Autism Spectrum Disorders: A Systematic Review
Dove, D., Warren, Z., McPheeters, M. L., Taylor, J. L., Sathe, N. A., & Veenstra-VanderWeele, J. (2012) · Pediatrics · doi:10.1542/peds.2012-0683 · Cited by 115
Self-citationThe Autism Impact Measure (AIM): Initial development of a new tool for treatment outcome measurement
Kanne, S. M., Mazurek, M. O., Sikora, D., Bellando, J., Branum-Martin, L., Handen, B., Katz, T., Freedman, B., Powell, M. P., & Warren, Z. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1862-3 · Cited by 114
“As a result, psychopharmacological and behavioral treatments have largely focused on cooccurring symptoms such as irritability, aggression, hyperactivity, or anxiety (Aman et al. 2004; McPheeters et al. 2011), or on cognitive or language functioning (Matson 2007; Warren et al. 2011b).”
BackgroundSelf-citationSleep in Autism Spectrum Disorders
Veatch, O. J., Maxwell-Horn, A. C., & Malow, B. A. (2015) · Current Sleep Medicine Reports · doi:10.1007/s40675-015-0012-1 · Cited by 112
“In addition, many medications that are prescribed to treat ASD symptoms and comorbid psychiatric conditions also affect sleep; some of the most commonly reported adverse events are insomnia or hypersomnolence [85].”
McCoy, S. M., & Morgan, K. (2019) · Autism · doi:10.1177/1362361319861579 · Cited by 136
“A systematic review showed that those taking risperidone had an average weight gain of 2.7–2.8 kg compared with a placebo group, and those taking aripiprazole had an average weight gain of 1.3–2.0 kg compared with the placebo (McPheeters et al., 2011).”
BackgroundInfluentialWhat Can Physicians Learn from the Neurodiversity Movement?
(2012) · AMA Journal of Ethics · doi:10.1001/virtualmentor.2012.14.6.oped1-1206 · Cited by 113
Nikoo, M., Radnia, H., Farokhnia, M., Mohammadi, M.-R., & Akhondzadeh, S. (2015) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000063 · Cited by 112
“Reviewing the safety profile of Food and Drug Administration–approved drugs for ADs, which includes several adverse effects (such as weight gain, metabolic abnormalities, and tardive dyskinesia), safe profile of NAC is more appealing for treating children experiencing ADs.(5,6) However, NAC could not positively affect…”
BackgroundResultInfluentialQuintana, D. S., Westlye, L. T., Hope, S., Nærland, T., Elvsåshagen, T., Dørum, E., Rustan, Ø., Valstad, M., Rezvaya, L., Lishaugen, H., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.103 · Cited by 111
Potential biomarkers in psychiatry: focus on the cholesterol system
Woods, A. G., Sokolowska, I., Taurines, R., Gerlach, M., Dudley, E., Thome, J., & Darie, C. C. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01543.x · Cited by 105
“Although no indicated medications exist for ASD, children with ASD are sometimes prescribed atypical antipsychotics for ASD symptoms or symptoms associated with comorbitities [140].”
BackgroundWang, L., Mandell, D. S., Lawer, L., Cidav, Z., & Leslie, D. L. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1649-y · Cited by 105
Treatment of Smith–Lemli–Opitz syndrome and other sterol disorders
Svoboda, M., Christie, J. M., Eroğlu, Y., Freeman, K. A., & Steiner, R. D. (2012) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31347 · Cited by 109
“Psychotropic medications, especially atypical antipsychotics, are commonly prescribed pharmacological treatments for many neurodevelopmental disorders, including autism and intellectual disability [Zarcone et al., 2001; McPheeters et al., 2011].”
BackgroundLee, J., Lee, T. S., Lee, S., Jang, J., Yoo, S., Choi, Y., & Park, Y. R. (2022) · JMIR Research Protocols · doi:10.2196/35960 · Cited by 130
“Well-designed interventions, such as risperidone and aripiprazole, have been reported to have strong and beneficial effects [8,9].”
BackgroundNutritional and Therapeutic Characteristics of Camel Milk in Children: A Systematic Review
Zibaee, S., Hosseini, S. M. A.-R., Yousefi, M., Taghipour, A., Kiani, M. A., & Noras, M. R. (2015) · Electronic physician · doi:10.19082/1523 · Cited by 111
Prosocial effects of oxytocin in two mouse models of autism spectrum disorders
Teng, B. L., Nonneman, R. J., Agster, K. L., Nikolova, V. D., Davis, T. T., Riddick, N. V., Baker, L. K., Pedersen, C. A., Jarstfer, M. B., & Moy, S. S. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.038 · Cited by 98
Sprengers, J. J., van Andel, D. M., Zuithoff, N. P. A., Keijzer-Veen, M. G., Schulp, A. J. A., Scheepers, F. E., Lilien, M. R., Oranje, B., & Bruining, H. (2021) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.07.888 · Cited by 97
Politte, L. C., & McDougle, C. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3068-y · Cited by 103
Insular function in autism: Update and future directions in neuroimaging and interventions
Nomi, J. S., Molnar-Szakacs, I., & Uddin, L. Q. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.10.015 · Cited by 113
Neural Mechanisms Underlying Repetitive Behaviors in Rodent Models of Autism Spectrum Disorders
Gandhi, T., & Lee, C. C. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.592710 · Cited by 88
“Besides, in controlled clinical trials, some of these pharmacological medications also reduce repetitive behaviors, but with potential side-effects that limit the widespread usage of these drugs in the treatment of ASD and as such is not approved by the FDA for repetitive disorders (McPheeters et al., 2011; Sharma and…”
BackgroundRumball, F. (2019) · Review Journal of Autism and Developmental Disorders · doi:10.1007/s40489-018-0133-9 · Cited by 92
“Whist it is beyond the scope of this article to provide a full overview of the use of psychopharmacology in ASD, the reader is referred to McPheeters et al. (2011) for a review of this topic.”
BackgroundObesity in children with developmental and/or physical disabilities
Bandini, L. G., Danielson, M. L., Esposito, L. E., Foley, J. T., Fox, M. H., Frey, G. C., Fleming, R. K., Krahn, G. L., Must, A., Porretta, D. L., et al. (2015) · Disability and health journal · doi:10.1016/j.dhjo.2015.04.005 · Cited by 104
Serotonin rebalances cortical tuning and behavior linked to autism symptoms in 15q11-13 CNV mice
Nakai, N., Nagano, M., Saitow, F., Watanabe, Y., Kawamura, Y., Kawamoto, A., Tamada, K., Mizuma, H., Onoe, H., Watanabe, Y., et al. (2017) · Science Advances · doi:10.1126/sciadv.1603001 · Cited by 89
Hsia, Y., Wong, A. Y. S., Murphy, D., Simonoff, E. A., Buitelaar, J. K., & Wong, I. C. K. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3263-x · Cited by 101
Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder
Madden, J. M., Lakoma, M. D., Lynch, F. L., Rusinak, D., Owen‐Smith, A. A., Coleman, K. J., Quinn, V. P., Yau, V. M., Qian, Y., & Croen, L. (2016) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-016-2946-7 · Cited by 111
Reprint of: Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders
Israelyan, N., & Margolis, K. G. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.023 · Cited by 100
Kirsten, T. B., Queiroz-Hazarbassanov, N., Bernardi, M. M., & Felicio, L. F. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.02.027 · Cited by 83
Sharma, R., Rahi, S., & Mehan, S. (2019) · Toxicology Reports · doi:10.1016/j.toxrep.2019.10.019 · Cited by 83
“There are a variety of approachable drug therapies used clinically to provide symptomatic relief in autistic patients, such as aripiprazole (ARP) [63], memantine (MEM) [18], donepezil (DNP) [34] and citalopram (CTP) [44] in attenuation of behavioral alterations.”
BackgroundInfluentialAmodeo, D. A., Jones, J. H., Sweeney, J. A., & Ragozzino, M. E. (2014) · Autism Research · doi:10.1002/aur.1395 · Cited by 79
“The complex pharmacology of a drug like risperidone, while potentially having procognitive effects, may also lead to severe and unwanted side effects, for example, weight gain and sedation [Aman, De Smedt, Derivan, Lyons, & Findling, 2002; Dove et al., 2012; Findling et al., 2000; McPheeters et al., 2011; Rummel-Kluge…”
BackgroundMasi, A., Lampit, A., Glozier, N., Hickie, I. B., & Guastella, A. J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.143 · Cited by 78
Owen-Smith, A. A., Bent, S., Lynch, F. L., Coleman, K. J., Yau, V. M., Pearson, K. A., Massolo, M. L., Quinn, V., & Croen, L. A. (2015) · Research in Autism Spectrum Disorders · doi:10.1016/j.rasd.2015.05.002 · Cited by 78
“Only two medications are approved by the Federal Food and Drug Administration (FDA) for the treatment of ASD – the antipsychotics Risperidone and Aripiprazole – and both drugs target problem behavior (irritability) rather than the ASD core symptoms (Hendren, 2013; McPheeters et al., 2011).”
BackgroundPaliperidone for irritability in adolescents and young adults with autistic disorder
Stigler, K. A., Mullett, J. E., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2711-3 · Cited by 76
“In addition, persons with autism often require more than one medication to target a variety of comorbid symptoms such as anxiety, insomnia, or hyperactivity (McPheeters et al. 2011).”
BackgroundGhaleiha, A., Mohammadi, E., Mohammadi, M.-R., Farokhnia, M., Modabbernia, A., Yekehtaz, H., Ashrafi, M., Hassanzadeh, E., & Akhondzadeh, S. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0036-2 · Cited by 78
“This finding is congruent with the formerly evident concept that pharmacological treatments are more efficient in ameliorating comorbid symptoms than in ameliorating core deficits in patients with autism [41].”
Ghaleiha, A., Rasa, S. M., Nikoo, M., Farokhnia, M., Mohammadi, M.-R., & Akhondzadeh, S. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.07.043 · Cited by 77
“…efficient rved. eh). al., A pilot double-blind pl avior in children with medications for AD remains an active area of research and pharmacological approaches have attracted much more attention in recent decades for study in this field (Leskovec et al., 2008; McPheeters et al., 2011; Nazeer, 2011).”
Investigating Parenting Stress across Pediatric Health Conditions - A Systematic Review
Golfenshtein, N., Srulovici, E., & Medoff-Cooper, B. S. (2015) · Issues in Comprehensive Pediatric Nursing · doi:10.3109/01460862.2015.1078423 · Cited by 103
“Although not curable, symptom-treatment options exist (McPheeters et al., 2011).”
Siegel, M. S., Beresford, C. A., Bunker, M., Verdi, M., Vishnevetsky, D., Karlsson, C. D., Teer, O., Stedman, A., & Smith, K. A. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0019 · Cited by 74
“Two atypical antipsychotic medications, risperidone and aripiprazole, have established evidence for the treatment of irritability in children with ASD (Mcpheeters et al. 2011; Siegel and Beaulieu 2012).”
DeMayo, M. M., Song, Y. J. C., Hickie, I. B., & Guastella, A. J. (2017) · Pediatric Drugs · doi:10.1007/s40272-017-0248-y · Cited by 76
“There may also be an associated increase in extrapyramidal symptoms such as tremors and dyskinesia [6].”
BackgroundMazahery, H., Conlon, C. A., Beck, K. L., Mugridge, O., Kruger, M. C., Stonehouse, W., Camargo, C. A., Meyer, B. J., Tsang, B., Jones, B., et al. (2019) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3860-y · Cited by 88
Healthcare access for autistic adults: A systematic review
Calleja, S., Islam, F. M. A., Kingsley, J., & McDonald, R. (2020) · Medicine · doi:10.1097/md.0000000000020899 · Cited by 66
Yu, Y., Chaulagain, A., Pedersen, S. A., Lydersen, S., LEVENTHAL, B. L., Szatmári, P., Aleksić, B., Ozaki, N., & Skokauskas, N. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-2477-9 · Cited by 79
“However, most studies focus on the disorder as a whole [20, 47, 48], while only few studies have been focused on pharmacotherapy against RRBs symptoms in ASD specifically.”
BackgroundKirsten, T. B., Chaves-Kirsten, G. P., Bernardes, S., Scavone, C., Sarkis, J. E., Bernardi, M. M., & Felicio, L. F. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134565 · Cited by 65
Bachmann, C. J., Manthey, T., Kamp-Becker, I., Glaeske, G., & Hoffmann, F. (2013) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2013.05.028 · Cited by 63
“Nevertheless, the level of evidence for the majority of those treatments is only moderate (Hurwitz, Blackmore, Hazell, Williams, & Woolfenden, 2012; McPheeters et al., 2011; Williams, Wheeler, Silove, &Hazell, 2010).”
BackgroundPharmacotherapy of autism spectrum disorders
Benvenuto, A., Battan, B., Porfirio, M. C., & Curatolo, P. (2012) · Brain and Development · doi:10.1016/j.braindev.2012.03.015 · Cited by 72
Mohammadi, M.-R., Yadegari, N., Hassanzadeh, E., Farokhnia, M., Yekehtaz, H., Mirshafiee, O., & Akhondzadeh, S. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3182a9339d · Cited by 61
“As its secondary effects, risperidone has some beneficial effects on the core symptoms of autism.(21) As described previously, amantadine can target 2 separate domains in the pathogenesis of autism (both the glutamate system and immunologic dysregulation).”
BackgroundPharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial
DeVane, C. L., Charles, J. M., Abramson, R. K., Williams, J. E., Carpenter, L. A., Raven, S., Gwynette, F., Stuck, C. A., Geesey, M. E., Bradley, C., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2271 · Cited by 60
Chan, J. S. Y., Deng, K., & Yan, J. H. (2020) · Autism · doi:10.1177/1362361320977645 · Cited by 68
“There is limited support for the use of medication to improve core ASD symptoms, particularly for difficulty with communication and social interaction (McPheeters et al., 2011).”
BackgroundAwareness of Autism in Primary School Teachers
Arif, M. M., Niazy, A., Hassan, B., & Ahmed, F. (2013) · Autism Research and Treatment · doi:10.1155/2013/961595 · Cited by 82
Ethical Considerations for Interdisciplinary Collaboration with Prescribing Professionals
Newhouse-Oisten, M. K., Peck, K. M., Conway, A. A., & Frieder, J. E. (2017) · Behavior Analysis in Practice · doi:10.1007/s40617-017-0184-x · Cited by 63
Meeking, M. M., MacFabe, D. F., Mepham, J. R., Foley, K. A., Tichenoff, L. J., Boon, F. H., Kavaliers, M., & Ossenkopp, K. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109794 · Cited by 64
Hendouei, F., Moghaddam, H. S., Mohammadi, M. R., Taslimi, N., Rezaei, F., & Akhondzadeh, S. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13076 · Cited by 65
Lipina, T. V., Fletcher, P. J., Lee, F. H., Wong, A. H. C., & Roder, J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.197 · Cited by 66
Manning‐Courtney, P., Murray, D. S., Currans, K., Johnson, H., Bing, N. M., Kroeger-Geoppinger, K., Sorensen, R., Bass, J., Reinhold, J., Johnson, A. J., et al. (2012) · Emerald Group Publishing Limited eBooks · doi:10.1016/j.cppeds.2012.08.001 · Cited by 93
Wang, C.-C., Lin, H., Chan, Y., Gean, P., Yang, Y. K., & Chen, P. S. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000473 · Cited by 64
“Current FDA-approved medicines for ASD have been approved for regulation of the dopamine and 5-HT systems (McDougle et al., 2005; McPheeters et al., 2011).”
BackgroundDiagnosis and management of autism in childhood
Blenner, S., Reddy, A., & Augustyn, M. (2011) · BMJ · doi:10.1136/bmj.d6238 · Cited by 56
Downs, J. M., Hotopf, M. H., Ford, T. J., Simonoff, E. A., Jackson, R., Shetty, H., Stewart, R. J., & Hayes, R. D. (2015) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-015-0780-7 · Cited by 62
“Two atypical antipsychotics in particular are most commonly used, risperidone and aripiprazole, which have been demonstrated to be effective in reducing “irritability” in children with ASD, but show limited impact on the core features of ASD [7].”
BackgroundResultBrix, M. K., Ersland, L., Hugdahl, K., Grüner, R., Posserud, M.-B. R., Hammar, Å., Craven, A. R., Noeske, R., Evans, C. J., Walker, H. B., et al. (2015) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2015.00365 · Cited by 69
Laue, H. E., Korrick, S., Baker, E., Karagas, M. R., & Madan, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-72386-9 · Cited by 68
Crawford, M., Gold, C., Odell‐Miller, H., Thana, L., Faber, S. E. M., Aßmus, J., Bieleninik, Ł., Geretsegger, M., Grant, C., Maratos, A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21590 · Cited by 72
Khaliq, A., Mishra, A. K., Niroula, A., Baba, W., Shaukat, M. N., & Rabbani, A. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.105531 · Cited by 72
Lamberti, M., Siracusano, R., Italiano, D., Alosi, N., Cucinotta, F., Rosa, G. D., Germanò, E., Spina, E., & Gagliano, A. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0183-3 · Cited by 57
Metadata
- Authors
- McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J.
- Affiliations
- Vanderbilt University (US)
- ORCID
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2011-05-01
- Volume
- 127
- Issue
- 5
- Pages
- e1312-e1321
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2121150539
- Cited by
- 356
- References
- 55
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 16 · 2023: 16 · 2022: 19 · 2021: 17 · 2020: 23 · 2019: 22 · 2018: 27 · 2017: 28 · 2016: 20 · 2015: 28 · 2014: 25 · 2013: 42 · 2012: 41
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PEDIATRICS (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- autism spectrum disorder, medical treatment, children, risperidone, aripiprazole, behavioral problems, repetitive behavior, adverse effects, serotonin reuptake inhibitors, stimulant medication, antipsychotic drugs, quality of evidence
- MeSH terms
- Aripiprazole, Child, Child Development Disorders, Pervasive, Child, Preschool, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluoxetine, Humans, Male, Patient Compliance, Piperazines, Prognosis, Serotonin Antagonists, Severity of Illness Index, Antipsychotic Agents, Citalopram, Quinolones, Randomized Controlled Trials as Topic, Treatment Outcome, Risperidone, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.